250 related articles for article (PubMed ID: 35186955)
1. Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles.
Juan A; Del Mar Noblejas-López M; Arenas-Moreira M; Alonso-Moreno C; Ocaña A
Front Cell Dev Biol; 2021; 9():805336. PubMed ID: 35186955
[TBL] [Abstract][Full Text] [Related]
2. Proteolysis targeting chimeras (PROTACs) in cancer therapy.
Ocaña A; Pandiella A
J Exp Clin Cancer Res; 2020 Sep; 39(1):189. PubMed ID: 32933565
[TBL] [Abstract][Full Text] [Related]
3. PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs.
Maneiro M; De Vita E; Conole D; Kounde CS; Zhang Q; Tate EW
Prog Med Chem; 2021; 60():67-190. PubMed ID: 34147206
[TBL] [Abstract][Full Text] [Related]
4. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
[TBL] [Abstract][Full Text] [Related]
5. Targeted protein degradation by PROTACs.
Neklesa TK; Winkler JD; Crews CM
Pharmacol Ther; 2017 Jun; 174():138-144. PubMed ID: 28223226
[TBL] [Abstract][Full Text] [Related]
6. Preclinical and Clinical Advances of Targeted Protein Degradation as a Novel Cancer Therapeutic Strategy: An Oncologist Perspective.
Yang X; Yin H; Kim RD; Fleming JB; Xie H
Target Oncol; 2021 Jan; 16(1):1-12. PubMed ID: 33369705
[TBL] [Abstract][Full Text] [Related]
7. Controlled Delivery of BET-PROTACs: In Vitro Evaluation of MZ1-Loaded Polymeric Antibody Conjugated Nanoparticles in Breast Cancer.
Cimas FJ; Niza E; Juan A; Noblejas-López MDM; Bravo I; Lara-Sanchez A; Alonso-Moreno C; Ocaña A
Pharmaceutics; 2020 Oct; 12(10):. PubMed ID: 33086530
[TBL] [Abstract][Full Text] [Related]
8. Proteolysis-targeting chimeras for targeting protein for degradation.
Qi J; Zhang G
Future Med Chem; 2019 Apr; 11(7):723-741. PubMed ID: 30706727
[TBL] [Abstract][Full Text] [Related]
9. Targeting Protein Kinases Degradation by PROTACs.
Yu F; Cai M; Shao L; Zhang J
Front Chem; 2021; 9():679120. PubMed ID: 34277564
[TBL] [Abstract][Full Text] [Related]
10. PROTACs- a game-changing technology.
Konstantinidou M; Li J; Zhang B; Wang Z; Shaabani S; Ter Brake F; Essa K; Dömling A
Expert Opin Drug Discov; 2019 Dec; 14(12):1255-1268. PubMed ID: 31538491
[No Abstract] [Full Text] [Related]
11. Design and pharmaceutical applications of proteolysis-targeting chimeric molecules.
Liang Y; Nandakumar KS; Cheng K
Biochem Pharmacol; 2020 Dec; 182():114211. PubMed ID: 32866456
[TBL] [Abstract][Full Text] [Related]
12. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
13. Smart PROTACs Enable Controllable Protein Degradation for Precision Cancer Therapy.
Chen L; Wan X; Shan X; Zha W; Fan R
Mol Diagn Ther; 2022 May; 26(3):283-291. PubMed ID: 35471699
[TBL] [Abstract][Full Text] [Related]
14. Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras.
Wang Y; Han L; Liu F; Yang F; Jiang X; Sun H; Feng F; Xue J; Liu W
Colloids Surf B Biointerfaces; 2020 Apr; 188():110795. PubMed ID: 31991291
[TBL] [Abstract][Full Text] [Related]
15. The clinical advances of proteolysis targeting chimeras in oncology.
Xie H; Liu J; Alem Glison DM; Fleming JB
Explor Target Antitumor Ther; 2021; 2(6):511-521. PubMed ID: 36046114
[TBL] [Abstract][Full Text] [Related]
16. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.
Gu S; Cui D; Chen X; Xiong X; Zhao Y
Bioessays; 2018 Apr; 40(4):e1700247. PubMed ID: 29473971
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACs.
Gao H; Wu Y; Sun Y; Yang Y; Zhou G; Rao Y
ACS Med Chem Lett; 2020 Oct; 11(10):1855-1862. PubMed ID: 33062164
[TBL] [Abstract][Full Text] [Related]
18. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
Zhang C; Han XR; Yang X; Jiang B; Liu J; Xiong Y; Jin J
Eur J Med Chem; 2018 May; 151():304-314. PubMed ID: 29627725
[TBL] [Abstract][Full Text] [Related]
19. PROTACs: A novel strategy for cancer therapy.
Liu J; Ma J; Liu Y; Xia J; Li Y; Wang ZP; Wei W
Semin Cancer Biol; 2020 Dec; 67(Pt 2):171-179. PubMed ID: 32058059
[TBL] [Abstract][Full Text] [Related]
20. Photopharmacology of Proteolysis-Targeting Chimeras: A New Frontier for Drug Discovery.
Zeng S; Zhang H; Shen Z; Huang W
Front Chem; 2021; 9():639176. PubMed ID: 33777902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
